CONSUMER NEWS    RECALLS    COMPLAINT FORM    SCAM ALERTS  


Complain about a product or service

Small Claims Guide | Class Actions | Lemon Law | FAQ | Resources | Newsletters | Spanish
Automotive    Education    Electronics    Family    Finance    Health    Homeowners    Shopping    Travel   
NEWS   Latest |  Archives |  Auto |  Cells, etc. |  Computers |  Financial |  Health |  Homeowners |  Parents |  Privacy |  Scams |  Seniors |  Travel

Merck Withdraws Vioxx After Negative Reactions Among Patients in Study



September 30, 2004
Giant drugmaker Merck today withdrew its Vioxx from the market, following indications that it can contribute to serious cardiovascular events including heart attacks and strokes.

Related Stories

First Vioxx Judgment Overturned On Appeal
Merck Agrees to Pay $58 Million to Settle Vioxx Claims
Researchers Claim Merck Cooked Vioxx Data
Common Pain Relievers May Boost Muscle Mass
More Painkillers Can Cause More Pain
Merck Caves, Agrees To $4.85 Billion Vioxx Settlement
New York Sues Vioxx Maker over Drug’s Risks
Merck Wins Vioxx Case In Illinois
Judge Rules Out Vioxx "Super" Class Action
FDA Critic Blasts Merck's Vioxx Replacement
Merck Loses New Orleans Vioxx Case
Merck Wins Latest Vioxx Suit
Vioxx Study Authors Backtrack On Claim
Older Painkillers May Increase Heart Attack Risk
More about Vioxx
---
Other NSAIDs
Bextra
Celebrex
Dangers of Other Vioxx-Type Drugs
Vioxx Alternatives
Aleve Ingredient Seen as Health Risk

Vioxx (chemical name rofecoxib) is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of arthritis and other diseases.

The Food and Drug Administration (FDA) today acknowledged the voluntary withdrawal and issued a Public Health Advisory to inform patients of the action and to advise them to consult with a physician about alternative medications.

The negative reactions were observed among study patients taking Vioxx compared to patients receiving placebo. The study was being done in patients at risk of developing recurrent colon polyps.

"Merck did the right thing by promptly reporting these findings to FDA and voluntarily withdrawing the product from the market," said Acting FDA Commissioner Dr. Lester M. Crawford.

"Although the risk that an individual patient would have a heart attack or stroke related to Vioxx is very small, the study that was halted suggests that, overall, patients taking the drug chronically face twice the risk of a heart attack compared to patients receiving a placebo."

Dr. Crawford added that FDA will closely monitor other drugs in this class for similar side effects. "All of the NSAID drugs have risks when taken chronically, especially of gastrointestinal bleeding, but also liver and kidney toxicity. They should only be used continuously under the supervision of a physician."

FDA approved Vioxx in 1999 for the reduction of pain and inflammation caused by osteoarthritis, as well as for acute pain in adults and for the treatment of menstrual pain. It was the second of a new kind of NSAID (Cox-2 selective) approved by FDA. Subsequently, FDA approved Vioxx to treat the signs and symptoms of rheumatoid arthritis in adults and children.

At the time that Vioxx and other Cox-2 selective NSAIDs were approved, it was hoped that they would have a lower risk of gastrointestinal ulcers and bleeding than other NSAIDs (such as ibuprofen and naproxen). Vioxx is the only NSAID demonstrated to have a lower rate of these side effects.

Merck contacted FDA on September 27, 2004, to request a meeting and to advise the agency that the long-term study of Vioxx in patients at increased risk of colon polyps had been halted. Merck and FDA officials met the next day, September 28, and during that meeting the company informed FDA of its decision to remove Vioxx from the market voluntarily.

Recently other studies in patients taking Vioxx have also suggested an increased risk of cardiovascular events. FDA was in the process of carefully reviewing these results, to determine whether further labeling changes were warranted, when Merck informed the agency of the results of the new trial and its decision to withdraw Vioxx from the market, the agency said.



Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.


Consumer News

July 9 2008

Recent Recalls & Safety Alerts

Print, mail, etc.




FREE CONSUMER NEWSLETTERS

The Daily Consumer
Afternoons M-F

Sign up now!


Consumer News & Alerts
Every Sunday

Sign up now!


Knowledge is free.
Knowledge is power.

Back to the top |


Home | Rogues Gallery | Good Guys | Complaint Form | News | Recalls | Search | Site Map | FAQ |
Consumer Resources | Small Claims Guide | Lemon Law | Newsletter | Contact Us
Advertise With Us | Testimonials | Newsroom | RSS Feeds | Video | Job Postings

Advertisement


Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2008 ConsumerAffairs.com Inc.  All Rights Reserved.